[Study of a programmed release preparation of betahistine mesylate in the treatment of Ménière's disease (author's transl)].
The efficacy/tolerance ratio of a new form of betahistidine salt was studied in patients with Ménière's disease or isolated tinnitus. The study was divided into two stages: first, a conventional open trial, then a comparative cross-over trial. Analysis of efficacy scores showed that the drug was clearly effective in relieving vertigo and associated symptoms and had no clinical or biochemical side-effects.